Mental health technology deals are increasingly sold on continuity. A larger platform can offer more providers, more forms of care, and fewer disruptions when a patient changes jobs, insurance, or treatment needs. That promise is compelling. It also creates a data governance problem that is easy to miss during integration.
When two platforms combine, the transaction may bring together therapy records, assessment responses, care navigation history, claims, wearable streams, voice data, behavioral signals, and algorithmic risk scores. Each dataset was collected in a particular relationship and for a particular purpose. Corporate ownership may change in a day. The meaning of the patient’s permission does not.
Recent deals show how quickly the issue is becoming practical. Spring Health’s acquisition of Alma creates a platform supporting more than 170 million people and plans to use shared infrastructure, data, and technology to improve continuity. Such combinations may improve care while also expanding the ways that highly sensitive information can be connected, interpreted, and reused.
Mental health technology M&A therefore needs a consent continuity standard. Consent continuity means preserving the original context, purpose, limits, and patient choices attached to data as it moves into a new corporate and technical environment. It is not another generic notice sent after closing. It is an integration control that should be completed before datasets, analytics pipelines, or AI models are combined.
Map the original permission, not only the data
Most integration teams begin with a technical inventory: what data exists, where it sits, and whether the fields can be mapped. A consent continuity review adds the questions that determine whether those fields should be joined at all.
For every material category, the buyer should document who collected it, the privacy notice or authorization in effect, the stated purpose, permitted recipients, retention period, and any deletion or withdrawal request. This record should travel with the data. Otherwise, an integration team may know what a field contains without knowing what may legitimately be done with it.
HIPAA applies to covered entities and their business associates, but many consumer health applications sit outside that framework. The Federal Trade Commission’s health app guidance explains that other federal rules may still apply. A broad claim that a combined platform is compliant says little unless the company can trace the obligations attached to each source.
Treat inferred data as health data
The most sensitive information in a mental health platform may not be what a patient knowingly typed into a form. It may be what a system inferred from response time, language, voice, sleep, movement, gaze, or patterns of engagement.
The FTC advises companies to take a broad view of health information, including data that enables an inference about a person’s health. That principle should shape M&A diligence. Buyers need an inventory of derived scores, behavioral labels, embeddings, model features, and predictions, along with the raw data and purpose that produced them.
An anxiety risk score is not simply another record. It is an interpretation created within a particular model and care context. Moving it into a broader platform can change its audience and consequence. A score created to guide a clinician should not quietly become an input for marketing, eligibility, individual level employer reporting, or unrelated product development.
Separate the right to receive data from the right to expand its use
A transaction can permit data to change hands without granting unlimited permission to repurpose it. Integration plans should therefore separate three decisions: whether information can transfer, whether it can be combined with new sources, and whether it can support a new purpose such as model training or product analytics.
When the intended use falls outside the original commitment, the responsible options are to obtain meaningful permission, keep the dataset segregated, limit it to the original purpose, or delete it. Revising a privacy policy after closing is a weak substitute. In its action involving genetic testing company 1Health.io, the FTC challenged the retroactive expansion of data sharing without adequate notice and consent. Mental health platforms should treat that case as a warning against assuming that new ownership resets old promises.
The same review must extend to AI assets. Training datasets, derived features, and models can retain value from information long after a raw record is removed. The FTC has warned that companies may be required to delete models or algorithms developed using unlawfully obtained data. Consent review cannot stop at the database layer.
Give patients a consequential choice
A notice that only announces new ownership and points to a revised policy is insufficient. Patients should be told which information will enter the combined environment, what new uses are proposed, whether additional organizations will gain access, and how to refuse secondary uses.
The choice must have practical effect. A person should not lose essential care merely because they decline an unrelated analytics or model development use. Existing deletion and withdrawal requests must remain effective after migration, and new requests should propagate across backups, analytics systems, vendors, and training pipelines where applicable.
Make consent continuity auditable
Executives and boards should receive evidence, not reassurance. Useful measures include the percentage of data categories with verified provenance, the number of incompatible uses identified before integration, the share of records kept segregated, the time required to honor deletion requests, and the number of models reviewed for data permission conflicts.
No standard can remove every risk from consolidation. It can prevent technical integration from outrunning the relationship on which mental health care depends. Strong platforms will be able to show patients, clinicians, regulators, and partners why each use remains legitimate after the deal closes.
Care continuity is a worthy goal. Without consent continuity, however, a platform can become clinically smoother while making the patient’s data relationship harder to understand and control. Trust should survive the transaction with the same rigor as the data.
About Nargiza Noimann Zander
Nargiza Noimann-Zander is the founder of X-Technology and a researcher with 25+ years in neuroscience and psychotechnology. She leads research programs on emotional and cognitive recovery after cancer, dementia, and other chronic conditions, and collaborates with clinicians to design and evaluate evidence-based, AI-supported virtual- reality interventions. She is currently partnering with UAE clinics to integrate these tools into routine care pathways, with a focus on measurable outcomes and patient dignity.
